NVAX

NOVAVAX INC NVAX

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,777 of 2,925

Why it scores 18Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$56.70M

Quarter to Jun 30

Net income

$-53.39M

Quarter to Jun 30

Free cash flow

$-73.39M

Quarter to Jun 30

Operating margin

-96.8%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.14B total
SHAH CAPITAL MANAGEMENT
$133.44M-4.6%
BlackRock, Inc.
$131.38M+8.6%
STATE STREET CORP
$110.60M+30.9%
VANGUARD PORTFOLIO MANAGEMENT LLC
$71.67M+6.4%
VANGUARD CAPITAL MANAGEMENT LLC
$68.37M+1.8%
Sanofi
$64.81M0.0%
D. E. Shaw & Co., Inc.
$53.23M-26.7%
GEODE CAPITAL MANAGEMENT, LLC
$39.64M+7.9%
TWO SIGMA INVESTMENTS, LP
$38.54M+565.4%
COATUE MANAGEMENT LLC
$36.14M0.0%
BANK OF AMERICA CORP /DE/
$32.18M-48.5%
GOLDMAN SACHS GROUP INC
$28.33M+113.4%
Sculptor Capital LP
$24.11M0.0%
UBS Group AG
$17.61M-58.2%
MILLENNIUM MANAGEMENT LLC
$16.66M-54.1%
CITADEL ADVISORS LLC
$15.97M+50.9%
Allianz Asset Management GmbH
$14.88M-15.1%
NORTHERN TRUST CORP
$13.64M-4.1%
TSP Capital Management Group, LLC
$13.37M+2.1%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$12.69M-2.0%
Point72 Asset Management, L.P.
$11.50M-14.4%
VANGUARD FIDUCIARY TRUST CO
$10.22M-2.0%
JUPITER ASSET MANAGEMENT LTD
$10.08MNew
AQR CAPITAL MANAGEMENT LLC
$8.50M+705.5%
Bank of New York Mellon Corp
$8.00M+8.8%
See all 270 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NVAX

Earnings Per Share

13fpro.ai/company/NVAX

Loading ratio trend…

NVAX key financials by period

Reported revenue, net income and operating margin by fiscal year, from NOVAVAX INC's annual filings on SEC EDGAR.

NOVAVAX INC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.1B$440.3M40.3%
FY 2024$682.2M$-187.5M-36.5%
FY 2023$983.7M$-545.1M-57.6%
FY 2022$2.0B$-657.9M-32.5%
FY 2021$1.1B$-1.7B-147.1%
FY 2020$475.6M$-418.3M-87.6%
Source: NVAX filings on SEC EDGAR →

Companies similar to NVAX

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

NVAX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About NOVAVAX INC (NVAX): stock profile, AI score and financials

NOVAVAX INC (NVAX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVAX at 18.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,777 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.9) and profitability (9.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NOVAVAX INC reports quarterly revenue of $56.7M, net income of $-53.4M, an operating margin of -96.8%. Top institutional holders of NVAX by reported 13-F value include SHAH CAPITAL MANAGEMENT, BlackRock, STATE STREET, based on the most recent SEC filings. NVAX trades on the Nasdaq exchange and files with the SEC under CIK 1000694. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NOVAVAX INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1000694 →